Evaluation of Fluorescent Plasma Markers for in vivo Microscopy of the Microcirculation

Kimberley J. Reeves  Zoë L.S. Brookes  Malcolm W.R. Reed  Nicola J. Brown

Microcirculation Research Group, Academic Unit of Surgical Oncology, Department of Oncology, University of Sheffield, Sheffield, UK

Introduction

For many years our studies have employed FITC-albumin (BSA) to investigate interstitial fluorescence in both control and experimental models, including ischaemia-reperfusion injury, sepsis and cancer [1–3]. There has been debate in the literature as to the most biologically relevant...
fluorescent-macromolecule conjugate to use in microvascular-based research [4–6]. Despite previously published evidence that FITC-albumin induces phototoxicity [7–11] and photobleaching [12, 13], this has not been apparent in our previous experiments and is the subject of this study.

Fluorescein isothiocyanate (FITC) is probably the most frequently used fluorescent dye for study of the microcirculation, due to its solubility in aqueous media, relatively high quantum yield, availability and low cost [9, 13–17]. However, one of the major limitations of FITC conjugates is photobleaching, both in vitro and in vivo, whereby following light activation, the molecule is no longer visible [12, 13]. Recently, there has been increased use of tetramethylrhodamine isothiocyanate (TRITC) in studies of the microcirculation. Compared to FITC, TRITC demonstrates enhanced stability and is less sensitive to environmental conditions such as pH [4, 18, 19]. Other fluorescent dyes used less extensively include Texas Red, Oregon Green-514 and dichlorotriazinyl amino-fluorescein [18–21]. Two macromolecules are frequently conjugated to the fluorescent dyes to evaluate microvascular barrier function, namely BSA [4] and dextran, the latter being characterized by a range of molecular weights (MWs), good solubility and low toxicity [8, 17]. Without protein conjugation, fluorescent probes, due to their size and charge, leak through the endothelial barrier into the interstitium.

The use of fluorescent-conjugated macromolecules to study the microcirculation in vivo is based on two essential assumptions, namely that (1) the fluorescent conjugation does not alter the physicochemical properties of the macromolecules and (2) the fluorescent dye does not directly alter the physicochemical properties of the endothelial barrier, i.e. that the conjugates are inert in terms of the microcirculation. However, there is evidence that the light required to activate the fluorescent molecule may result in microvascular dysfunction due to phototoxicity, which appears to involve, at least in part, damage by reactive oxygen species [6, 22, 23]. Recently, a number of comparative studies have been performed to address these issues by investigating the properties of less well characterized commercially prepared fluorescent conjugates compared to FITC-albumin. Bingaman et al. [4], using FITC, TRITC, Oregon Green, dichlorotriazinyl aminofluorescein and Texas Red in vitro, demonstrated that addition of the macromolecule BSA to FITC resulted in changed physicochemical characteristics, including MW, charge and isoelectric point, which were not altered by controlling the experimental conditions. Thus, modulation of the physicochemical properties of the protein may alter protein mobility across the endothelial barrier and hence subsequent localization in the surrounding tissue interstitium. This may potentially result in incorrect conclusions relating to either barrier function or the nature of unlabelled protein interactions.

The second potential problem relating to the use of fluorescent dye conjugates to study the microcirculation is that of phototoxicity, which has been demonstrated both in vitro and in vivo, in particular for commercially prepared FITC-BSA [7–11]. Few studies have focused on whether the nature of the conjugates affects interpretation of the results [12–23]. In general, phototoxicity is related to the concentration of the fluorescent conjugate, excitation intensity, duration of exposure and the light dose used for activation [4, 9, 20]. Damage is related to the induction of reactive oxygen species, which is reduced by the administration of inhibitors [24]; this may not be immediately evident and is also cumulative [20]. Phototoxicity may be limited by reducing the fluorescent conjugate concentration and the light intensity, in addition to modifying the physicochemical characteristics of the dye [4, 6, 9]. A comparative in vitro study using commercially available fluorescent dye conjugates demonstrated that during continuous light excitation, phototoxicity occurred during shorter time periods with FITC-BSA when compared to 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-indacene-3-propioic acid (BODIPY)-FL-BSA, Texas Red-BSA and TRITC-BSA [20]. These studies emphasize the importance of controlling the light excitation dose and intensity and highlight the need to evaluate dye content and the nature of the fluorescent conjugate when selecting fluorescent molecules for microvascular studies.

This study aimed to evaluate the hypothesis that our ‘in-house’ preparation of FITC-BSA is a suitable fluorescent conjugate for intravital microscopy when compared with other routinely used fluorescent markers and that deconjugation results in the development of interstitial fluorescence. Initially, the in vitro stability of different fluorescent dye conjugates was evaluated. Then we performed an in vivo comparative evaluation of the stability of microvascular function in the cremaster muscle, as assessed by diameter and vascular fluorescence, using commercial and ‘in-house’ fluorescent conjugates. Finally, we assessed whether repeated administration of FITC-BSA and varying the illumination duration resulted in microvascular instability using the in vivo dorsal microcirculatory chamber (DMC) skeletal muscle model in conscious animals.
Materials and Methods

Animals
Experiments were performed on male C3H/HeN mice (n = 78) weighing 20–30 g (model 1: cremaster muscle) and Wistar rats (n = 18) weighing 80–280 g (model 2: DMC) obtained from the University of Sheffield (UoS) Field Laboratories and held in the animal facility for at least 1 week before experimentation. Animals were exposed to a 12/12-hour light/dark cycle in a humidity- and temperature-controlled environment and allowed access to water and food ad libitum. All procedures were performed in accordance with the UK Home Office Animal Procedures Act (1986), Project License numbers 40/2343 (model 1) and 40/2110 (model 2).

Protein-Fluorescent Conjugation
FITC-dextran (MW 70 kDa; FD-70), TRITC-dextran (MW 65–76 kDa; T1162), FITC-BSA (Sigma; MW 66 kDa; A9771), FITC (F7250), TRITC (T3163) and BSA (MW 66 kDa; A7030) were purchased from Sigma-Aldrich (Poole, UK). Dextran and BSA have similar MWs.

FITC-BSA Conjugation (UoS)
BSA was conjugated to FITC as previously described [3, 25]. Briefly, 0.037 g of FITC isomer I and 2 g of BSA were dissolved in 20 ml of bicarbonate solution (0.12 g Na₂CO₃, 0.74 g NaHCO₃, water, pH 9.0). The covered container of conjugate was mixed and then stirred for 24 h, followed by centrifugation at 6,000 g for 10 min. The supernatant was placed into washed cellulose dialysis tubing (MW 12,000; D-0530, Sigma-Aldrich), which was then immersed in 2 litres of Nairn’s solution (17 g NaCl, 0.692 g NaH₂PO₄.H₂O, 2.14 g Na₂HPO₄, pH 7.4) and stirred for 12 h. The Nairn’s solution was changed 24 h later for 4 litres of fresh Nairn’s solution and stirred for a further 12 h. The conjugate was stored in the dark as frozen 0.5-ml aliquots until required.

TRITC-BSA Conjugation
BSA conjugated to TRITC was prepared as previously described [12]. Briefly, 60 mg of BSA was dissolved in 10 ml of 0.05 M borate buffer (0.049 M Na₂B₂O₂.H₂O, pH 9.24, 20°C) containing 0.4 M NaCl and placed in dialysis tubing (MW 12,000; D-0530, Sigma-Aldrich). Dye solution was prepared by dissolving 10 mg of TRITC in 50 ml of 0.05 M borate buffer. The covered container of dye with the dialysis bag was stirred for 24 h. The labeled material was then dialysed against 2 litres of glucose-free Ringer’s solution. The dialysate was changed 24 h later for 2 litres of fresh glucose-free Ringer’s solution. The conjugate was stored in 0.5-ml aliquots in the dark at ~20°C until required.

FITC-Dextran, TRITC-Dextran and FITC-BSA
The three molecules were purchased as conjugated powder (Sigma, UK). A total of 200 mg of either TRITC-dextran or FITC-dextran was dissolved in 4 ml of distilled water, and 2 ml each were dialysed as described above. For FITC-BSA (Sigma), 100 mg was dissolved in 10 ml of 10 mM Tris (pH 7.0), and 5 ml were dialysed as described above. All samples were stored in 0.5-ml aliquots at ~20°C in the dark until required.

The dye content of the fluorescent conjugates conjugated to macromolecules are as follows: FITC-BSA (UoS), 1 molecule of BSA per 5.9 molecules of FITC; FITC-BSA (Sigma), 1 molecule of BSA per 7–12 molecules of FITC; TRITC-BSA, 1 molecule of BSA per 6 molecules of TRITC; FITC-dextran, 1 molecule of FITC per 1 molecule of glucose, and TRITC-dextran, 1 molecule of TRITC per 100 glucose residues.

Measurement of Bound Fluorescent Conjugate
The bound fluorescent conjugates of FITC-BSA (Sigma), FITC-BSA (UoS), TRITC-BSA, FITC-dextran and TRITC-dextran were measured in vitro and in vivo. In vitro, the conjugates were measured following incubation at 37°C in a water bath for different time periods, i.e. 0, 2, 4 and 8 h. In vivo, FITC-BSA (Sigma), FITC-BSA (UoS), FITC-dextran and TRITC-dextran (0.25 ml/100 g) were administered into the carotid artery, and blood samples were taken at 0 h (immediately after injection) and 2 h.

The samples (pre-dialysis and dialysis) from both in vitro and in vivo studies were separated into bound (>30 kDa) and unbound (<30 kDa) fluorescent conjugate fractions using a Centrifree Micropartition device (30 kDa; Millipore, UK) according to the manufacturer’s instructions. Fluorescence was detected using a spectrophotometer (Perkin Elmer). FITC-BSA and FITC-dextran were excited at 495 nm, and fluorescence was detected between 470 and 650 nm. TRITC-BSA and TRITC-dextran were excited at 547 nm, and fluorescence was detected at 572 nm. Spectrophotometer readings were compared between bound and unbound fluorescent conjugate fractions.

Surgical Preparation
Model 1: Cremaster. Mice weighing 20–30 g (age 7 weeks) were anaesthetized with an intra-peritoneal injection of a mixture of Hypnorm (Janssen Pharmaceutical) 0.5 ml/kg, Diazemuls (Dumex) 0.5 ml/kg and water [1:1:2 (v/v)]. A tracheotomy was performed, and a Portex cannula bevelled at one end was inserted to preserve the airway. An oesophageal thermistor probe (Fluke Ltd., UK) was inserted and connected to a digital thermometer (52II, Fluke Ltd.). The left carotid artery was cannulated and connected to a pressure transducer. The transducer allowed arterial blood pressure to be monitored continuously using WinDaq (DATAQ, USA). The animal was placed on a warming pad (Cole-Parmer Instruments Co., UK) attached to a Perspex animal board, which allowed maintenance of body temperature (37°C). The cremaster muscle was prepared as previously described [26].

Model 2: DMC. Rats weighing 80–90 g (age 5 weeks) underwent training which involved placement in a restraining device daily for increasing periods of time up to 10 min in the 2-week period prior to sterile surgery (weeks 1 and 2). When rats weighed 130–140 g (week 3), they were anaesthetized intra-peritoneally with 0.1 ml/100 g Hypnorm/diazepam (1:1), and the DMC was implanted as previously described [27, 28], with modifications by the authors [11]. The animals were then allowed to recover from surgery in week 3 before recommencing training in weeks 4–5. Experiments were then performed in weeks 6–10.

In vivo Microscopy
Animals were transferred to the stage of an Optiphot-2 Nikon fluorescent microscope (Nikon Ltd., UK) equipped with a tungsten lamp for transmitted light and a mercury arc lamp for epilumination fluorescent light microscopy. The microscope was horizontally mounted for evaluation in model 2. Transmitted light was used for pre-selecting areas of the microcirculation. Im-


Reeves/Brookes/Reed/Brown
ages of the preparation were viewed through a ×10 objective (0.03 numerical aperture, Nikon). A filter cube interposed into the path of a mercury arc lamp allowed blue (450–490 nm) or green (530–560 nm) light to be selected for epi-illumination of the skeletal muscle microcirculation. The excitation power densities ranged from 24.8 to 26.4 mW for green light and from 16.9 to 19.2 mW for blue light. Images of the preparation were monitored using a CCD camera (KP-161, Hitachi, UK), displayed on a high-resolution monitor (PVM-1443, Sony, UK) and recorded by a video data recorder (VDR-3000, Holdan Ltd., UK) onto CD-RW (650 MB; Sony) for later off-line analysis. This included the addition of time and date information (DTG1, NG Systems, UK). Animals were allowed an equilibration period of 30 min before the experimental illumination periods. During this time, the preparation was briefly scanned with low-level transmitted light, and suitable areas of interest (AOIs) were identified for study. In model 1, this involved selecting 3–4 AOIs in the cremaster muscle microcirculation to include all of the following types of vessels in each animal: A1 (100–140 μm), A2 (60–100 μm) and A4 (10–30 μm) arterioles, and V1 (110–150 μm), V2 (70–110 μm), V3 (40–70 μm) and V4 (10–40 μm) venules.

All vessels included had a straight length of at least 500 μm. No branches were present in the area of analysis. Interstitial fluorescence was quantified by placing three 90-μm2 boxes 50 μm apart immediately adjacent to the vessel of interest, avoiding areas that included underlying capillaries. The mean fluorescence of the 3 sites was evaluated. Similarly, three 90-μm2 boxes 50 μm apart were placed inside the vessel to quantify intravascular fluorescence.

For the subcutaneous maximus muscle microcirculation (model 2), 3 areas were selected using the criteria detailed above to include arterioles and venules (random locations, but in the same location in each animal), avoiding areas that included underlying capillaries. The mean fluorescence of the 3 sites was evaluated. Similarly, three 90-μm2 boxes 50 μm apart were placed inside the vessel to quantify intravascular fluorescence. The subcutaneous maximus muscle microcirculation (model 2), 3 areas were selected using the criteria detailed above to include arterioles and venules (random locations, but in the same location in each animal), avoiding areas that included underlying capillaries. The mean fluorescence of the 3 sites was evaluated. Similarly, three 90-μm2 boxes 50 μm apart were placed inside the vessel to quantify intravascular fluorescence.

Experimental Groups

Model 1. Mice were randomly allocated to 5 experimental groups: FITC-BSA (Sigma) (n = 18), FITC-BSA (UoS) (n = 12), FITC-dextran (n = 18), TRITC-dextran (n = 18) and TRITC-BSA (n = 12). For 12 animals in each group (n = 6 each for pre-dialysis and dialysis), the fluorescent conjugate (0.25 ml/100 g) was administered into the carotid artery at t = 0 min. Following a 30-min stabilization period (t = –30 to 0), a baseline recording of the AOI was made at t = 0. During illumination with blue light, the AOIs were recorded for 1 min at 10-min intervals for a total of 90 min, with a final reading at t = 120 min, when a recording of the entire cremaster preparation was made. As a control, 6 animals in each group were illuminated only at t = 0 and t = 120. Mice were also allocated to 2 extra groups, i.e. FITC alone and FITC-BSA. The experimental protocol was as above, except recordings were made every minute for 10 min, as the FITC alone immediately leaked into the interstitium, thus obscuring the preparation.

Model 2. In week 6, conscious rats were randomly allocated to either the 180-min acute study (week 6 only, n = 6 experiments for 180 min), the 24-hour acute study (week 6 only, n = 6 experiments for 24 h) or the weekly 180-min chronic study (weeks 6–10, n = 6 experiments for the 180-min protocol repeated weekly on 5 occasions). In the 180-min acute studies, FITC-BSA (0.25 ml/100 g) was administered into the tail vein, and the AOIs were illuminated with blue light for 1 min every 12 min for 180 min (total = 15 min). In the 24-hour acute studies, FITC-BSA was adminis-

Measurements

In anesthetized mice (model 1), temperature, heart rate and blood pressure were recorded on-line every 10 min for the entire 120-min experimental period. In model 1, vessel diameters and interstitial and vascular fluorescence were recorded, and in model 2, vessel diameters and interstitial fluorescence were recorded. Measurements were analysed off-line using a Viglen IV/25 computer (Viglen, UK) and an image analysis software package (CapiScope version 3.7.1.0, KK Research Technology Ltd., UK). Each of the 3–4 selected AOIs was intermittently exposed to fluorescent light at specified intervals for a maximum of 1 min with the aim of limiting any phototoxic damage [3]. For each animal at each time point, measurements of diameter and interstitial fluorescence were made at exactly the same anatomical position. External vessel diameter (including lumen and vessel wall) was measured in microns (micrometres). Fluorescence was quantified using an arbitrary grey scale (0–255), with interstitial fluorescence determined from the mean of 3 distinct areas (900 μm2) adjacent to the selected vessels and vascular fluorescence determined from the mean of 3 distinct areas (900 μm2) within the vessel using the image analysis software CapiScope.

Statistical Analysis

All data are expressed as means ± standard error of the mean. Measurements of bound fluorescent conjugate are expressed as percentages and evaluated using a paired t test. Statistical significance was evaluated using two-way ANOVA on ranks followed by the Mann-Whitney U test for nonparametric data to determine differences between in vivo experimental groups; within-group variation was assessed using one-way ANOVA on ranks followed by the Wilcoxon test for paired data. All results were considered significantly different at p < 0.05.

Results

Measurement of Bound Fluorescent Conjugate

Separation studies were performed and a spectrofluorimeter was used to assess bound versus unbound fluorescent conjugate in vivo and in vitro. In vitro data demonstrated that FITC-BSA (UoS) had the highest percentage of bound fluorescent conjugate (96%) at 37°C, compared to FITC-dextran and TRITC-BSA, with TRITC-dextran (pre-dialysis and post-dialysis) having the lowest percentage of bound fluorescent conjugate (74%) at all of the time points. However, over the incubation period, all of the fluorescent conjugates became unbound (fig. 1a). In vivo data showed that FITC-BSA (UoS) had the highest percentage of bound fluorescent conjugate both at 0 and 2 h after injection into the animal, with TRITC-dextran (pre-dialysis and post-dialysis) having
the lowest percentage of bound fluorescent conjugate (fig. 1b). However, over the 2-hour period, all of the fluorescent conjugates became partially deconjugated (fig. 1b), but this was not significant for FITC-BSA (UoS).

**Physiological Variables**

There were no differences in oesophageal temperature, cremaster muscle temperature or blood pressure between the control and fluorescent conjugate- and light-treated groups in either in vivo model.

**Model 1: Cremaster – Diameter**

There were no differences in arteriolar diameter or venule diameter between the controls and fluorescent conjugate- and light-treated groups for any of the fluorescent conjugates for the entire duration of the study (table 1).

**Model 1: Cremaster – Interstitial Fluorescence**

Interstitial fluorescence data only from V1, V4, A1 and A4 vessels are presented, as the V2, V3, A2 and A3 vessels demonstrated the same pattern of response as the first- and fourth-order venules and arterioles, respectively.

TRITC-BSA. At the beginning of the experiment, fluorescent conjugate contained within the vessels was clearly visible, but by 30 min, fluorescence was no longer visible, such that the preparation appeared black. A fluorescent conjugate-conjugate was prepared using the FITC-BSA method, which yielded similar results. Thus

---

**Fig. 1.** a In vitro measurement of the bound fluorescent component of FITC-BSA (UoS), FITC-BSA (Sigma), FITC-dextran, TRITC-BSA and TRITC-dextran (predialysis) at various time points (0, 2, 4 and 8 h) after incubation at 37°C. *p < 0.05: significant difference compared to FITC-BSA (t test). n = 6 per group. b In vivo measurement of the bound fluorescent component of FITC-BSA (UoS), FITC-BSA (Sigma), FITC-dextran and TRITC-dextran (predialysis) at various time points (0 and 2 h). *p < 0.05: significant difference compared to FITC-BSA (UoS) (t test). n = 6 per group.
Table 1. Arteriolar (A) and venule (V) vessel diameters at different time points after administration of FITC-BSA (UoS), FITC-BSA (Sigma), FITC-dextran and TRITC-dextran

<table>
<thead>
<tr>
<th>Vessel diameter, μm</th>
<th>A1 vessels</th>
<th>A4 vessels</th>
<th>V1 vessels</th>
<th>V4 vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 min</td>
<td>120 min</td>
<td>0 min</td>
<td>120 min</td>
</tr>
<tr>
<td>FITC-BSA (UoS)</td>
<td>103.8 ± 5.4</td>
<td>104.5 ± 4.1</td>
<td>18.9 ± 3.6</td>
<td>20.5 ± 2.8</td>
</tr>
<tr>
<td>FITC-BSA (Sigma)</td>
<td>100.8 ± 3.7</td>
<td>101.7 ± 2.3</td>
<td>18.7 ± 2.4</td>
<td>19.7 ± 2.1</td>
</tr>
<tr>
<td>FITC-dextran</td>
<td>112.3 ± 4.4</td>
<td>111.2 ± 6.1</td>
<td>20.2 ± 2.7</td>
<td>18.9 ± 1.7</td>
</tr>
<tr>
<td>TRITC-dextran</td>
<td>106.7 ± 5.9</td>
<td>103.3 ± 5.9</td>
<td>19.8 ± 1.4</td>
<td>20.1 ± 1.3</td>
</tr>
<tr>
<td>Control</td>
<td>104.5 ± 4.7</td>
<td>107.1 ± 5.3</td>
<td>16.4 ± 2.4</td>
<td>18.4 ± 3.0</td>
</tr>
</tbody>
</table>

Data are presented for the three other fluorescent conjugates.

**FITC-BSA (UoS).** There was no increase in interstitial fluorescence over the 120-min experiment for any of the vessels compared to controls and baseline (fig. 2a, b).

**FITC-BSA (Sigma).** There was an increase ($p < 0.05$) in interstitial fluorescence by 60 min for V1 ($5.4 ± 1.8$), by 50 min for V4 ($4.2 ± 2.1$), by 90 min for A1 ($8.6 ± 9.3$) and by 80 min for A4 vessels ($8.1 ± 3.8$) compared to the baseline, which was then maintained for the duration of the study. At 120 min, the FITC-BSA (Sigma) group demonstrated significantly ($p < 0.05$) more leakage than the FITC-BSA (UoS) group for all vessel types (fig. 2a).

**FITC-Dextran.** There was no increase in interstitial fluorescence for the initial 40 min, but thereafter there was a significant increase ($p < 0.05$) adjacent to V1, A1 and A4 vessels compared to baseline ($t = 0$). This increase occurred at 30 min in V4 vessels. By 120 min, there was significantly more leakage in the FITC-dextran group compared with the FITC-BSA (UoS) group for all vessel types (fig. 2a, b).

**TRITC-Dextran.** There was an increase ($p < 0.05$) in interstitial fluorescence by 30 min compared to the baseline for all vessel types in all groups, which was maintained for the duration of the study. At 120 min, the TRITC-dextran group demonstrated more leakage in all vessels ($p < 0.05$) than the FITC-BSA (UoS) group (fig. 2a).

**Dialysed Conjugates.** FITC-BSA (Sigma), FITC-dextran and TRITC-dextran were all dialysed prior to injection. The dialysed conjugates did not demonstrate reduced interstitial fluorescence (data not presented).

**FITC Alone Compared to FITC-BSA (UoS).** There was a significant difference in fluorescence between FITC alone and FITC-BSA (UoS) over the 10 min in all vessel types, which occurred 1 min after administration and peaked after 8 min (V1 $18.8 ± 1.9$, V4 $20.4 ± 2.0$, A1 $14.8 ± 1.4$ and A4 $14.9 ± 0.9$). Since FITC is not conjugated to a protein molecule, this leaks immediately from the vessels, hence the shorter duration of this experiment.

**Model 1: Cremaster – Vascular Fluorescence**

**FITC-BSA (UoS), FITC-BSA (Sigma) and FITC-BSA (Sigma Dialysis).** There were no differences in vascular fluorescence over the 120 min in any of the vessel types compared to control or $t = 0$ (fig. 2c) or between the fluorescent conjugates.

**FITC-Dextran.** Vascular fluorescence remained constant until 40 min, after which there was an increase in V4 and A4 vessels ($p < 0.05$), which occurred later in V1 and A1 vessels, at 120 min (fig. 2c).

**TRITC-Dextran.** There was a significant increase ($p < 0.05$) in vascular fluorescence by 30 min compared to baseline for V4 and A4 vessels, but this increase occurred later in V1 and A1 vessels, at 80 min (fig. 2c).

**Dialysed Conjugates.** Vascular fluorescence for the dialysed groups showed a similar pattern of results when compared to the undialysed groups.

**Model 2: DMC – Diameter**

There were no changes in arteriole diameter (A1 $86.5 ± 6.3$ μm, A3 $33.1 ± 2.9$ μm) or venule diameter (V1 $217.7 ± 14.6$ μm, V4 $59.2 ± 6.2$ μm) between the control and fluorescent conjugate- and light-treated groups, either for an individual experiment or at the end of the 10-week study period.

**Model 2: DMC – Interstitial Fluorescence**

In the 180-min acute study, there were no increases in interstitial fluorescence adjacent to the V4 vessels over 180 min when compared to $t = 0$ following intermittent epi-
Fig. 2. a The level of fluorescence in the interstitium adjacent to V1, V4, A1 and A4 vessels after administration of FITC-BSA (UoS), FITC-BSA (Sigma), TRITC-dextran and FITC-dextran (data normalized to baseline; n = 6/group). *p < 0.05: significant difference for TRITC-dextran from t = 0 (Wilcoxon test); †p < 0.05: significant difference for FITC-dextran from t = 0 (Wilcoxon test).

Fig. 2. b A, B V4 vessel at t = 0 min (A) and t = 120 min (B) after administration of FITC-BSA (UoS) showing no macromolecular leak. Vessels appear white and the interstitium black. C, D V2 and V3 vessels at t = 0 (C) after administration of TRITC-dextran showing no interstitial fluorescence and at t = 120 (D) showing interstitial fluorescence. Scale bar = 50 μm.
illumination for a total of 15 min (p > 0.05; fig. 3a). However, in the 24-hour acute study, there was significant leakage from the venules at 240 min (p < 0.05) when compared to t = 0, despite the lower total exposure time of 4 min. This increased steadily up to 24 h, at which time there had been a total of 6 min of light exposure (p < 0.05; fig. 3b). In the repeat studies, there was no increase in leakage on each occasion when compared to t = 0. This remained the case even at week 10, when the microcirculation had been exposed to 5 weekly doses of FITC-BSA (UoS), with 15 min of intermittent epi-illumination on each occasion (p > 0.05; fig. 3c). Additionally, there appeared to be no side effects or morbidity associated with repeated administration of FITC-BSA (UoS), evaluated according to Home Office regulations (PPL 40/2110), which include vocalization, struggling, licking/guarding, weight loss, piloerection, hunched position and hypothermia.

**Discussion**

This is the first in vivo study to investigate the stability of different fluorescent-protein conjugates in vitro and compare microcirculatory responses using two in vivo microvascular models. The investigation was undertaken as previously published data had identified limitations associated with the in vivo use of FITC-BSA, including photobleaching and phototoxicity, and had suggested that alternative protein-fluorescent conjugates may be more appropriate for in vivo evaluation of microvascular responses [4, 9, 18–21]. Despite this evidence, our laboratory had not encountered problems using FITC-BSA in vivo, presumably due to the preparation protocol.

Initially, in vitro studies were performed to evaluate the percentage of bound versus unbound conjugate following incubation at 37°C for varying periods up to 8 h.
Following dialysis of all preparations, FITC-BSA (UoS) demonstrated the highest level of conjugation at all time points investigated. In vivo cremaster muscle microcirculation studies were performed using all the fluorescent-protein conjugates; vascular fluorescence, interstitial fluorescence, vessel diameter and serum levels of bound versus unbound fluorescent conjugate were evaluated. There were no changes in vascular fluorescence with either of the FITC-BSA conjugates, whereas there was a small but significant increase in vascular fluorescence with FITC-dextran and TRITC-dextran in fourth-order vessels. The significance of this finding is unclear, although it may in part explain the increase in interstitial fluorescence observed. One possible explanation could be that increased water permeability across the small fourth-order vessels produced a filtration effect, thus increasing vascular fluorescence. Throughout the study, FITC-BSA (UoS) resulted in the least interstitial fluorescence following intermittent excitation using blue light and a total light exposure of 11 min, with no change in vessel diameter for the 2-hour experimental period, suggesting minimal de-conjugation and/or phototoxicity. Intermittent excitation of TRITC-dextran resulted in the greatest increase in interstitial fluorescence when compared to the other fluorescent-protein conjugates. Interstitial fluorescence was compared following administration of FITC alone or FITC-BSA; FITC demonstrated immediate leakage (after 1 min), whereas FITC-BSA (UoS) remained within the vessels. After 10 min, FITC-BSA remained within the vessels, but FITC alone had leaked, with vessels appearing black with a white edge; in addition, FITC had been removed from the interstitium, presumably by lymph vessels. Serum analysis of the bound versus unbound protein conjugates revealed that despite dialysis, imme-

---

**Fig. 3.**

**a** Mean ± SEM (n = 6) interstitial fluorescence adjacent to postcapillary venules (V4) within the skeletal muscle of DMC-implanted rats following FITC-BSA administration and epi-illumination with blue light for 1 min every 12 min, for a total of 180 min. Studies were performed at week 6 after implantation of the DMC.

**b** Mean ± SEM (n = 6) interstitial fluorescence adjacent to postcapillary venules (V4) within the skeletal muscle of DMC-implanted rats following FITC-BSA administration and epi-illumination with blue light for 1 min at 0, 1, 2, 4, 8 and 24 h. Studies were performed at week 6. *p < 0.05: significant difference compared to t = 0 (Wilcoxon test).

**c** Mean ± SEM (n = 6) interstitial fluorescence adjacent to postcapillary venules (V4) within the skeletal muscle of DMC-implanted rats following FITC-BSA administration and 6 min of epi-illumination with blue light. Studies were performed during weeks 6–9, with the same light protocol each week over 4 weeks.
Immediately (0–5 min) following in vivo administration, unbound fluorescent molecules were detected, which probably accounts for the increased interstitial fluorescence observed in vivo at the beginning of the study for the FITC-dextran and TRITC-dextran conjugates. This is in addition to the likely deconjugation over time, as demonstrated in the in vitro studies. When considering all fluorescent-protein conjugates, FITC-BSA (UoS) demonstrated the highest percentage of binding in both in vitro and in vivo studies.

A further observation was that systemic administration of TRITC-BSA resulted in intravascular fluorescence for the first 30 min of observation, following which fluorescence was no longer detectable either in the vessels or the surrounding tissue. This may have been due to extensive initial photobleaching or because following leakage and subsequent clearance there was minimal fluorescence for detection. However, in contrast, TRITC-dextran fluorescence could not be detected. Despite the differences in microvascular variables identified between the BSA groups in vivo, this is unlikely to be due to the ratio of dye to protein, which was similar for each protein-conjugate. However, for the dextran studies, different numbers of glucose molecules (FITC-dextran 1:1, TRITC-dextran 1:100) may in part explain the differences observed between these groups. Therefore, our data suggest that FITC-BSA (UoS) is the most stable fluorescent conjugate for studying interstitial fluorescence and vessel diameter in murine cremaster muscle microcirculation using in vivo microscopy when compared to commercial FITC-BSA, TRITC-dextran and FITC-dextran using intermittent light excitation for a total of 11 min. However, the all fluorescent conjugates benefited from dialysis prior to in vivo administration, which removes a proportion of the unbound component present.

FITC-BSA (UoS) was then evaluated using a second in vivo model, the dorsal window chamber implanted in rats. There was no FITC-BSA (UoS) leakage during the first 180 min of observation (15 min of illumination), confirming the findings obtained with model 1 that FITC-BSA (UoS) is a suitable fluorescent conjugate for in vivo microvascular studies, using this particular administration route, conjugation protocol and light dose for up to 3 h. However, in the acute 24-hour studies, although there was no significant interstitial fluorescence between 0 and 2 h, in contrast, between 4 and 24 h, increased leakage was apparent even with reduced total epi-illumination (6 min). These data suggest that FITC-BSA is stable for 4 h, after which time deconjugation occurs and results in leakage into the interstitium. Repeat-dose for up to 3 h. However, in the acute 24-hour studies, although there was no significant interstitial fluorescence between 0 and 2 h, in contrast, between 4 and 24 h, increased leakage was apparent even with reduced total epi-illumination (6 min). These data suggest that FITC-BSA is stable for 4 h, after which time deconjugation occurs and results in leakage into the interstitium. Repeat administration studies were also carried out between weeks 6 and 10, during which time the 180-min acute study was performed on 5 occasions, and confirmed that this protocol can be used repeatedly at weekly intervals without causing damage to the microcirculation. Furthermore, no observable long-term side effects occurred in conscious animals in response to repeated FITC-BSA administration.

There are two main potential mechanisms explaining an increase in interstitial fluorescence, namely phototoxicity and deconjugation. Phototoxicity may occur following extensive exposure of a fluorescent conjugate to light. The excitation induces a photochemical response, generating reactive oxygen species, which leads to the induction of structural changes and damage to the vessel wall resulting in interstitial fluorescence. Microvascular dysfunction and leakage induced by fluorescent conjugate light activation have been reported in hamster cheek pouch with FITC-dextran-70 and in rat cremaster with FITC-BSA. These data are in contrast to those generated in the current study. The likely explanation is that the response is dependent upon the excitation time, with leakage evident following continuous exposure (excitation light) for 10 min, whereas intermittent light exposure (for 1 min at 10-min intervals) is less damaging to the tissue, with reduced phototoxicity. In addition, we observed no leukocyte or thrombocyte adhesion (in either model), which often occurs following vascular damage.

An alternative mechanism is that the protein may become unbound and remain in the vasculature, whereas the fluorescent conjugate leaks into the interstitium. Deconjugation, as opposed to phototoxicity, is the most likely explanation for the leakage observed in the current study, as vessel diameters remained unchanged throughout each experiment, and increased venular permeability has previously been shown to be accompanied by increased capillary diameter. However, the sensitivity of the in vivo microscopy system used in the current study may not be sufficient to monitor small but significant changes in capillary diameter. In addition, interstitial fluorescence occurred throughout the cremaster preparation and not just in the activated areas, suggestive of deconjugation. Our in vitro and in vivo binding studies demonstrated a greater proportion of bound fluorescent conjugate for the FITC-BSA (UoS) preparation compared to the other fluorescent conjugate preparations evaluated.

An interesting in vitro study using rat erythrocytes demonstrated that phototoxicity occurs after a shorter
period of time using continuous excitation of FITC-BSA (Sigma) compared to BODIPY-FL-BSA, Texas Red-BSA and TRITC-BSA. TRITC-BSA also appeared to be the least phototoxic of the four fluorescent dyes tested [20]. Conversely, our results demonstrated no evidence of phototoxicity using FITC-BSA, whereas after 30 min of intermittent illumination, TRITC-BSA was no longer visible. The differences observed between this and previous studies are probably due to the shorter period of illumination used in the current study, with only brief intermittent exposure to light for a maximum of 1 min at any one time. Microvascular dysfunction following FITC-BSA administration has previously been shown to be dependent on excitation light intensity [6], with continuous excitation of FITC-BSA for 10 min resulting in leakage, whereas intermittent light exposure (15 s at 0, 5 and 10 min) appeared not to induce damage, with no significant leakage by 60 min [6]. Another study which investigated the fluorescent-protein conjugate leakage response to 1-NiMe demonstrated that in control experiments (animals received fluorescent conjugate but no 1-NiMe and were exposed to intermittent light of 5–15 s), FITC-BSA and TRITC-BSA did not leak over time [20]. The rat DMC acute 180-min study (model 2) confirmed these observations. However, in acute 24-hour studies, there was no significant interstitial fluorescence between 0 and 2 h, whereas between 4 and 24 h, increased leakage was apparent even with reduced total epi-illumination, supporting our hypothesis that FITC-BSA becomes unbound and leaks from the vasculature after 4 h, rather than damage being induced by photoactivation.

Therefore, in summary on the basis of the current studies, FITC-BSA prepared according to our specified protocol is a useful conjugate for determining interstitial fluorescence in skeletal muscle of different species, as well as in microcirculation preparations in conscious and anaesthetized animals. Both models support previous in vivo studies demonstrating no alterations in interstitial fluorescence of FITC-BSA for up to 4 h when using intermittent excitation [1, 2, 23, 29]. In conclusion, the interstitial fluorescence observed with protein fluorescent conjugates is due to their ability to deconjugate over time, as demonstrated both in vivo and in vitro, which emphasizes the need for careful selection of fluorescent markers depending on the in vivo preparation and protocol under study.

Acknowledgements

We gratefully acknowledge the support of Sheffield Hospitals Charitable Trust (Grant number: RB104471) and Mrs. Sue Higham for technical assistance with the in vitro fluorescent conjugate experiments.

References


